Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04863157 · ClinicalTrials.gov registry record · NA

Survivor-Sleep Health Information Program

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
16
Enrollment target

NCT04863157: Completed NA study, sponsored by Dana-Farber Cancer Institute.

NCT04863157 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04863157, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

The purpose of the study is to learn if an educational program delivered to parents/guardians can help improve the sleep of children experiencing sleep problems after completing cancer treatment. The name of the intervention is Survivor-SHIP (Sleep Health Information Program).

Primary Outcome

Intervention acceptability will be assessed using the Satisfaction subscale of the Usability, Satisfaction, and Ease of use (USE) scale. Total scores will range from 0-11, with higher scores indicating better acceptability.

Interventions

  • BEHAVIORAL Survivor-SHIP

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-05-24
Est. Completion 2022-12-31
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT04863157 record still lists

NCT04863157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Survivor-SHIP is the first listed.

NCT04863157 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04863157 about?

NCT04863157 is a clinical study titled "Survivor-Sleep Health Information Program". The purpose of the study is to learn if an educational program delivered to parents/guardians can help improve the sleep of children experiencing sleep problems after completing cancer treatment. The name of the intervention is Survivor-SHIP (Sleep Health Information Program).

What is the current status of trial NCT04863157?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2021-05-24. Estimated completion is 2022-12-31.

What interventions are being tested in trial NCT04863157?

The interventions under investigation include: Survivor-SHIP (BEHAVIORAL).

Who is sponsoring clinical trial NCT04863157?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04863157's enrollment target sits among peer trials

16 1871st of 2000 higher than 120 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04863157, the US trial registry maintained by the National Library of Medicine. NCT04863157 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.